Literature DB >> 8004735

Simple narcotic kits for controlled-substance dispensing and accountability.

J R Maltby1, D A Levy, C J Eagle.   

Abstract

Operating rooms require a storage, dispensing and accounting system for restricted drugs which satisfies narcotics control authorities and is compatible with efficient care of patients. We describe narcotic kits containing fentanyl-morphine-midazolam, alfentanil-midazolam and sufentanil-midazolam, for general operating rooms, and two kits with larger quantities of fentanyl and sufentanil for cardiac operating rooms. The container for each kit is a video cassette holder which has a foam-rubber liner with sculpted depressions for each ampoule. Sealed kits are delivered each morning from pharmacy to the locked narcotics cupboard in the recovery room. On request, the recovery room nurse unlocks the cupboard and the anaesthetist signs out the required kit(s) for the day. A drug utilization form is enclosed with each kit, on which the anaesthetist records the amount of drug administered to each patient, and before returning the kit to the locked narcotics cupboard, the total amount of each drug used, discarded, and returned. Used kits are collected the following morning by a pharmacy technician who reconciles the contents and drug form of each kit. More than 40 staff anaesthetists and a similar number of residents have used the system for seven years, during which time 130,000 patients have passed through the operating rooms. Detection of one case of drug diversion by a staff anaesthetist was made partly by the control system, but mainly by behavioural changes. The system is simple, inexpensive, and effective and has been well received by the departments of pharmacy, anaesthesia, and nursing.

Entities:  

Mesh:

Year:  1994        PMID: 8004735     DOI: 10.1007/BF03009908

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  10 in total

1.  Controlled substance dispensing and accountability in United States anesthesiology residency programs.

Authors:  R L Klein; W C Stevens; H G Kingston
Journal:  Anesthesiology       Date:  1992-10       Impact factor: 7.892

2.  Substance abuse. Now, and for some time to come.

Authors:  C F Ward
Journal:  Anesthesiology       Date:  1992-10       Impact factor: 7.892

3.  Development of a comprehensive operating room pharmacy.

Authors:  A L Shafer; S R Lisman; M B Rosenberg
Journal:  J Clin Anesth       Date:  1991 Mar-Apr       Impact factor: 9.452

4.  Preventing unauthorized access to narcotics in the operating room.

Authors:  B L Partridge; M B Weinger; T J Sanford
Journal:  Anesth Analg       Date:  1990-11       Impact factor: 5.108

5.  Refractometer screening of controlled substances in an operating room satellite pharmacy.

Authors:  D L Gill; S R Goodwin; A K Knudsen; C Wade
Journal:  Am J Hosp Pharm       Date:  1990-04

6.  Use of refractometry to identify opioid-containing solutions.

Authors:  C J Eagle; J R Maltby; S Kryski; D Hardy
Journal:  Can J Anaesth       Date:  1994-03       Impact factor: 5.063

7.  Narcotics control in anesthesia training.

Authors:  G R Adler; F E Potts; R R Kirby; S LoPalo; G R Hilyard
Journal:  JAMA       Date:  1985-06-07       Impact factor: 56.272

8.  Control and accountability of controlled substance administration in the operating room.

Authors:  R J Moleski; S Easley; P G Barash; G Primer; N Q Shier; R I Schrier
Journal:  Anesth Analg       Date:  1985-10       Impact factor: 5.108

9.  Implementing an operating room pharmacy satellite.

Authors:  P J Powell; L Maland; J N Bair; J D McCall; K C Wong
Journal:  Am J Hosp Pharm       Date:  1983-07

10.  A reliable accounting system for controlled substances in the operating room.

Authors:  K A Schmidt; M D Schlesinger
Journal:  Anesthesiology       Date:  1993-01       Impact factor: 7.892

  10 in total
  1 in total

1.  Use of refractometry to identify opioid-containing solutions.

Authors:  C J Eagle; J R Maltby; S Kryski; D Hardy
Journal:  Can J Anaesth       Date:  1994-03       Impact factor: 5.063

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.